NCT03003065View on ClinicalTrials.gov

Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 28, 2014

Primary Completion Date

April 12, 2023

Study Completion Date

August 12, 2023

Conditions
CholangiocarcinomaTumorKlatskin Tumor
Interventions
DRUG

Temoporfin

A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours

Trial Locations (1)

Unknown

Endoscopy Centre, Prince of Wales Hospital, Shatin

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT03003065 - Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers | Biotech Hunter | Biotech Hunter